Navigation Links
Modigene Sets Record Date for Annual Meeting of Shareholders
Date:2/10/2009

NES-ZIONA, Israel, Feb. 10 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today announced that its board of directors has set the close of business on April 1, 2009 as the record date for shareholders entitled to vote at the Company's 2009 Annual Meeting of Shareholders. Modigene currently anticipates that the 2009 Annual Meeting will be held on May 21, 2009 in Miami, Florida at a location to be announced.

In addition, the Company wishes to inform shareholders that the deadline for submitting a timely shareholder proposal for potential inclusion in the proxy statement for the 2009 Annual Meeting of Shareholders has been set at February 28, 2009. In order for a shareholder proposal to be considered, it must be received by the Company on or prior to February 28, 2009 at its principal executive offices at 3 Sapir Street, Weizmann Science Park, Nes Ziona Israel 74140. Notices of proxy proposals should be sent to the attention of Shai Novik, President.

Modigene plans to file a proxy statement in connection with the 2009 Annual Meeting of Shareholders with the Securities and Exchange Commission (SEC) and advises its shareholders to read the proxy statement with care, as it will contain important information. Modigene intends to make the Company's proxy statement and its Annual Report on Form 10-K for the year ended December 31, 2008 available to shareholders through several channels. Shareholders may obtain a free copy of Modigene's 2009 proxy statement and any other relevant SEC documents via the SEC's web site at www.sec.gov, and also through the Company's website at www.modigeneinc.com. The proxy statement and these other documents, when available, may also be obtained free of charge by directing a request to Modigene at 3 Sapir Street, Weizmann Science Park, Nes Ziona, Israel 74140, Attention: Secretary.

Modigene's directors and named executive officers are authorized to participate in soliciting the support of the Company's shareholders in connection with the 2009 Annual Meeting. Shareholders may obtain information regarding the names and affiliations of these individuals in Modigene's Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and in the other filings by the Company with the SEC.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

    MODIGENE CONTACT:                        MEDIA CONTACT:
    Shai Novik, President                    Barbara Lindheim
    Modigene Inc.                            GendeLLindheim BioCom Partners
    Tel: +1 866 644-7811                     Tel: +1 212 918-4650
    Email: shai@modigeneinc.com


'/>"/>
SOURCE Modigene Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
2. Modigene to Present at the UBS Global Life Sciences Conference
3. Modigene to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
5. Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Modigene to Present at the Roth 2007 New York Investor Conference
7. AlloSource Distributes Record Amount of Tissue in 2008
8. OmniComm Systems, Inc. Experiences Record Year End Results - $18 Million in Signed Contracts for the Year 2008
9. Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians
10. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
11. Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 ... mission is to advance global health and highlight the greater good of clinical trial ... clinical trial volunteer. The vision of GGI is to serve as a philanthropic connector ...
(Date:2/23/2017)... ... February 22, 2017 , ... ... , have been named Fellows of the Society this year, the Fellows Committee ... the multidisciplinary fields of optics, photonics, and imaging as well as their service ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
Breaking Biology News(10 mins):